Candel Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Candel Therapeutics
CADL Stock  USD 8.82  0.01  0.11%   
Candel Therapeutics financial statements provide useful quarterly and yearly information to potential Candel Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Candel Therapeutics financial statements helps investors assess Candel Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Candel Therapeutics' valuation are summarized below:
Gross Profit
-20.7 M
Market Capitalization
134.3 M
Enterprise Value Revenue
821.9774
Revenue
31 K
Earnings Share
(1.73)
There are over one hundred nineteen available fundamental signals for Candel Therapeutics, which can be analyzed over time and compared to other ratios. We recommend to validate Candel Therapeutics' prevailing fundamental drivers against the all of the trends between 2010 and 2025. Market Cap is expected to rise to about 288.7 M this year. Enterprise Value is expected to rise to about 192.3 M this year

Candel Therapeutics Total Revenue

26,505

Check Candel Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Candel Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 1.2 M, Depreciation And Amortization of 596.5 K or Selling General Administrative of 11 M, as well as many indicators such as Price To Sales Ratio of 451, Dividend Yield of 0.0 or PTB Ratio of 4.35. Candel financial statements analysis is a perfect complement when working with Candel Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Candel Therapeutics Correlation against competitors.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.

Candel Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets73.2 M106.9 M55.3 M
Slightly volatile
Short and Long Term Debt Total10.7 M10.9 M4.6 M
Slightly volatile
Other Current Liabilities28.2 M26.8 M5.2 M
Slightly volatile
Total Current Liabilities39.4 M37.5 M7.6 M
Slightly volatile
Other Liabilities2.2 M2.3 M4.1 M
Pretty Stable
Property Plant And Equipment Net3.5 M2.7 M1.7 M
Slightly volatile
Accounts Payable225.2 K237 K372.2 K
Slightly volatile
Cash60.7 M102.7 M27.4 M
Slightly volatile
Non Current Assets Total3.9 M3.1 M2 M
Slightly volatile
Non Currrent Assets Other320.8 K329 K279.1 K
Slightly volatile
Other Assets358.9 K305.9 K289.4 K
Slightly volatile
Long Term Debt7.6 M14.2 M3.8 M
Slightly volatile
Cash And Short Term Investments68 M102.7 M52.8 M
Slightly volatile
Common Stock Total Equity189.9 K328.9 K165.8 K
Slightly volatile
Common Stock Shares Outstanding32.3 M31.7 M29.4 M
Slightly volatile
Non Current Liabilities Total2.9 M3 M40.4 M
Slightly volatile
Other Current Assets1.7 M1.1 M771.9 K
Slightly volatile
Total Liabilities32 M40.5 M47.3 M
Slightly volatile
Property Plant And Equipment Gross4.4 M7 M2.2 M
Slightly volatile
Total Current Assets69.3 M103.8 M53.4 M
Slightly volatile
Capital Stock241.6 K333.5 K169.8 K
Slightly volatile
Net Working Capital38.8 M20.4 M43.5 M
Pretty Stable
Common Stock287.3 K469 K181.1 K
Slightly volatile
Property Plant Equipment3.4 M6.3 M2 M
Slightly volatile
Current Deferred Revenue123.1 K129.6 K2.2 M
Slightly volatile
Deferred Long Term Liabilities537.4 K1 M322.5 K
Slightly volatile
Short and Long Term Debt5.1 M10.2 M2.9 M
Slightly volatile
Short Term Debt5.8 M10.5 M2 M
Slightly volatile
Long Term Debt Total448 K504 K549.5 K
Slightly volatile
Capital Surpluse115.3 M129.7 M141.4 M
Slightly volatile
Non Current Liabilities Other14.6 M16.4 M17.9 M
Slightly volatile

Candel Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income1.2 M2.4 M1.2 M
Slightly volatile
Depreciation And Amortization596.5 K864 K1.1 M
Slightly volatile
Selling General Administrative11 M14.1 M5.9 M
Slightly volatile
Total Revenue26.5 K27.9 K106.9 K
Slightly volatile
Other Operating Expenses26.4 M44.1 M16.7 M
Slightly volatile
Research Development17.4 M19.3 M10.8 M
Slightly volatile
Cost Of Revenue29 M27.6 M9.3 M
Slightly volatile
Total Operating Expenses23.9 M33.4 M14.5 M
Slightly volatile
Reconciled Depreciation1.1 M1.1 M291.3 K
Slightly volatile
Selling And Marketing Expenses549.6 K618.3 K674.1 K
Slightly volatile

Candel Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3 M5.3 M1.4 M
Slightly volatile
Begin Period Cash Flow46.6 M35.7 M32.5 M
Slightly volatile
Depreciation567.2 K990 K253 K
Slightly volatile
Capital Expenditures15.2 K16 K417.9 K
Slightly volatile
End Period Cash Flow61 M102.9 M27.7 M
Slightly volatile
Other Cashflows From Investing Activities151.3 K159.3 K27.5 M
Slightly volatile
Cash And Cash Equivalents Changes38.2 M43 M46.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4514751.3 K
Slightly volatile
Stock Based Compensation To Revenue12.4416.618.6576
Slightly volatile
Capex To Depreciation0.01540.01623.955
Pretty Stable
EV To Sales37.939.891.2 K
Slightly volatile
Payables Turnover53.751.1429.2267
Pretty Stable
Sales General And Administrative To Revenue51.9510144.3358
Slightly volatile
Research And Ddevelopement To Revenue82.1215080.2749
Slightly volatile
Capex To Revenue7.629.344.8075
Slightly volatile
Cash Per Share1.673.24081.7566
Slightly volatile
Days Payables Outstanding7.027.39330
Pretty Stable
Income Quality0.640.48980.6947
Pretty Stable
Net Debt To EBITDA1.622.75051.1843
Slightly volatile
Current Ratio2.632.76622.7963
Slightly volatile
Capex Per Share5.0E-45.0E-40.0144
Slightly volatile
Revenue Per Share0.00350.00390.0042
Slightly volatile
Interest Debt Per Share0.260.27710.1467
Slightly volatile
Debt To Assets0.130.10170.075
Slightly volatile
Days Of Payables Outstanding7.027.39330
Pretty Stable
Ebt Per Ebit1.131.140.9751
Slightly volatile
Quick Ratio2.632.76622.7963
Slightly volatile
Net Income Per E B T0.170.180.7898
Slightly volatile
Cash Ratio2.62.73534.9931
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.171.00061.0486
Slightly volatile
Fixed Asset Turnover0.02490.02620.1947
Slightly volatile
Debt Ratio0.130.10170.075
Slightly volatile
Price Sales Ratio4514751.3 K
Slightly volatile
Asset Turnover0.00250.00190.0025
Slightly volatile

Candel Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap288.7 M274.9 M209.4 M
Pretty Stable
Enterprise Value192.3 M183.2 M132.3 M
Pretty Stable

Candel Fundamental Market Drivers

Forward Price Earnings43.4783
Cash And Short Term Investments102.7 M

Candel Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Candel Therapeutics Financial Statements

Candel Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Candel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue129.6 K123.1 K
Total Revenue27.9 K26.5 K
Cost Of Revenue27.6 M29 M
Stock Based Compensation To Revenue 16.61  12.44 
Sales General And Administrative To Revenue 101.23  51.95 
Research And Ddevelopement To Revenue 149.67  82.12 
Capex To Revenue 9.34  7.62 
Ebit Per Revenue(319.44)(335.41)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Candel Therapeutics is a strong investment it is important to analyze Candel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Candel Therapeutics' future performance. For an informed investment choice regarding Candel Stock, refer to the following important reports:
How To Invest In Candel
Details
Is Candel Stock a good investment?
Details
What is Candel Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Candel Therapeutics Correlation against competitors.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.73)
Revenue Per Share
0.001
Return On Assets
(0.52)
Return On Equity
(4.81)
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY